TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39446377

Group type: EXPERIMENTAL
Intervention: Cohort 1: Vemurafenib plus cobimetinib plus atezolizumab
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cohort 2: Cobimetinib plus atezolizumab
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cohort 3: Bevacizumab plus atezolizumab
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall targeted therapy cohort
Number of subjects: 43
Study: 39446378

Group type: EXPERIMENTAL
Intervention: Genome sequencing for early-onset genetic conditions with established interventions
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Genome sequencing for neurodevelopmental disorders associated with seizures (optional)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Enrollment in genomic NBS study
Number of subjects: 4000
Study: 39446432

Group type: EXPERIMENTAL
Intervention: Deprexis intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 132
Study: 39446605

Group type: EXPERIMENTAL
Intervention: HLX07 monotherapy (1,000 mg IV Q2W)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HLX07 combined with serplulimab (200 mg IV day 1) and cisplatin (50 mg/m2)
Number of subjects: 50
Study: 39446647

Group type: EXPERIMENTAL
Intervention: ARSB fading intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UHB fading condition
Number of subjects: 0
Study: 39446648

Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral sex therapy (iCBST)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: internet-based mindfulness-based sex therapy (iMBST)
Number of subjects: 266

Group type: COMPARATOR
Intervention: waitlist control group
Number of subjects: 266
Study: 39446736

Group type: EXPERIMENTAL
Intervention: Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms (BSSVF-M)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard sacrospinous ligament suspension with sutures (SSLS)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: BSSVF-M
Number of subjects: 358
Study: 39446746

Group type: EXPERIMENTAL
Intervention: Facilitated directly observed therapy (DOT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Facilitated self-administered therapy (SAT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patient choice between facilitated DOT and facilitated SAT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3HP completion strategies
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3HP delivery strategies
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Training and care integration
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: COVID-19 treatment disruptions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Costs of 3HP facilitation
Number of subjects: 72
Study: 39446767

Group type: EXPERIMENTAL
Intervention: Mindful interoceptive exposure using a 2-minute attention exercise guided by a smartphone app over 8 weeks
Number of subjects: 31
Study: 39446982

Group type: EXPERIMENTAL
Intervention: Surgical intervention within less than 24 hours, especially in the cervical spine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure goals and steroids to maintain perfusion and decrease secondary injury
Number of subjects: 0
Study: 39447049

Group type: EXPERIMENTAL
Intervention: Performance of instrumental activities of daily living (Lawton and Brody scale)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dependence on activities of daily living (Barthel scale)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Joint damage (Hemophilia Joint Health Score)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 102
Study: 39447048

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Percutaneous intervention (PCI)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: SYNTAX score II-2020
Number of subjects: 1800
Study: 39447053

Group type: EXPERIMENTAL
Intervention: F2 antigen plus AS01 adjuvant
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: F2 antigen
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: F2 antigen or F2 antigen plus AS01 adjuvant (third dose)
Number of subjects: 130
Study: 39447094

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 90
Study: 39447170

Group type: EXPERIMENTAL
Intervention: Be-Prox intervention (6 modules over a 9-month period)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Control arm (no intervention during the study period)
Number of subjects: 708
Study: 39447384

Group type: EXPERIMENTAL
Intervention: Maternal stress responses during the still-face paradigm (FFSF-R)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Infant stress responses during the still-face paradigm (FFSF-R)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mother-infant synchrony during the still-face paradigm (FFSF-R)
Number of subjects: 31
Study: 39447517

Group type: EXPERIMENTAL
Intervention: SG001 240 mg every two weeks for 24 months or until disease progression, intolerable toxicities, or other study discontinuation criteria were met.
Number of subjects: 107
Study: 39447530

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (1-2 post-tetanic count) with repeated boluses of rocuronium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (1-3 train of four response) with repeated boluses of rocuronium
Number of subjects: 100
Study: 39447587

Group type: EXPERIMENTAL
Intervention: Severe asthma symptoms in adolescents with no clinical diagnosis of asthma
Number of subjects: 27272

Group type: EXPERIMENTAL
Intervention: Positive asthma tests in undiagnosed adolescents with severe symptoms
Number of subjects: 27272

Group type: EXPERIMENTAL
Intervention: Severe asthma symptoms in adolescents with clinician-diagnosed asthma
Number of subjects: 27272

Group type: EXPERIMENTAL
Intervention: Use of asthma medication in adolescents with severe symptoms
Number of subjects: 27272

Group type: EXPERIMENTAL
Intervention: Prevalence of asthma symptoms across different locations
Number of subjects: 27272
Study: 39447676

Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR) - 2 successive days of fasting (∼500 kcal/d) and 5 days of recovery per week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous calorie restriction (CCR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR)
Number of subjects: 60
Study: 39447717

Group type: EXPERIMENTAL
Intervention: Selective invasive management guided by ischemia stress imaging (IMG group)
Number of subjects: 1756

Group type: COMPARATOR
Intervention: Routine invasive strategy (INV group)
Number of subjects: 1756
Study: 39447716

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP) as an adjunct to veno-arterial (V-A) ECMO
Number of subjects: 0

Group type: COMPARATOR
Intervention: V-A ECMO alone
Number of subjects: 0
Study: 39447813

Group type: EXPERIMENTAL
Intervention: EGF-guided source ablation
Number of subjects: 85

Group type: COMPARATOR
Intervention: PVI only (for patients with EGF-identified sources)
Number of subjects: 85

Group type: COMPARATOR
Intervention: PVI only (for patients with no sources)
Number of subjects: 85
Study: 39447871

Group type: EXPERIMENTAL
Intervention: Port Delivery System with ranibizumab (100 mg/mL) Q24W
Number of subjects: 418

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab (0.5 mg)
Number of subjects: 418
Study: 39448029

Group type: EXPERIMENTAL
Intervention: CT-P13 (infliximab biosimilar)
Number of subjects: 751
Study: 39448057

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 868
Study: 39448077

Group type: EXPERIMENTAL
Intervention: Bilateral iTBS at 60-min intervals
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Bilateral iTBS at 30-min intervals
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Bilateral iTBS at 0-min intervals (once-daily)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 182
Study: 39448200

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab (n=23)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nivolumab+ipilimumab (n=21)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tumors with actionable genomic alterations (AGAs, n=12)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tumors without actionable genomic alterations (non-AGAs)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-profiled squamous cell carcinomas (non-AGAs+NP SCC, n=20)
Number of subjects: 44
Study: 39448207

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 60
Study: 39448216

Group type: EXPERIMENTAL
Intervention: PRIME programme (digital health-supported lifestyle intervention)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 16
Study: 39448218

Group type: EXPERIMENTAL
Intervention: 100 mg micronised progesterone (mP) per day in continuous combination with 1 mg oestradiol
Number of subjects: 520

Group type: COMPARATOR
Intervention: 0.5 mg norethisterone acetate (NETA) per day in continuous combination with 1 mg oestradiol
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 100 mg micronised progesterone (mP) with 1 mg oestradiol
Number of subjects: 520
Study: 39448217

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 1110
Study: 39448317

Group type: EXPERIMENTAL
Intervention: CT-μFR
Number of subjects: 242
Study: 39448323

Group type: EXPERIMENTAL
Intervention: Finger puppet (n = 40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pinwheel (n = 40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Abeslang puzzle (n = 40)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (n = 40)
Number of subjects: 160
Study: 39448350

Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance treatment
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance treatment followed by second-line enfortumab vedotin
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance treatment followed by platinum-based chemotherapy (PBC)
Number of subjects: 595
Study: 39448427

Group type: EXPERIMENTAL
Intervention: VMI ASPECTS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Total iodine content
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VMI infarct volume
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined predictors (VMI ASPECTS, total iodine content, VMI infarct volume)
Number of subjects: 84
Study: 39448701

Group type: EXPERIMENTAL
Intervention: Patients with delayed cerebral ischemia (DCI)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Patients without delayed cerebral ischemia (DCI)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Patients with modified Fisher score less than 3
Number of subjects: 587

Group type: COMPARATOR
Intervention: Patients with modified Fisher score greater than or equal to 3
Number of subjects: 587
Study: 39448724

Group type: EXPERIMENTAL
Intervention: High-Frequency Vibration (V)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cotton Roll (CR)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Elastomeric Wafer (EW)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Open Mouth (OM)
Number of subjects: 144
Study: 39448816

Group type: EXPERIMENTAL
Intervention: Prophylactic hydrocortisone (HC)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: BPD assessment at 40 weeks of postmenstrual age
Number of subjects: 404
Study: 39448906

Group type: EXPERIMENTAL
Intervention: Endoscopic papillectomy with stent placement
Number of subjects: 79

Group type: COMPARATOR
Intervention: Endoscopic papillectomy without stent placement
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stenting group (common bile duct stent placement)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stenting group (pancreatic duct stent placement)
Number of subjects: 79
Study: 39448911

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Bevacizumab and olaparib/PARPi
Number of subjects: 205
Study: 39448938

Group type: EXPERIMENTAL
Intervention: Exercise intervention in primary care following robot-assisted radical cystectomy
Number of subjects: 20
Study: 39448966

Group type: EXPERIMENTAL
Intervention: Spartalizumab (300 mg every 3 weeks) with platinum-doublet chemotherapy (PDC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spartalizumab with PDC and canakinumab
Number of subjects: 0
Study: 39448986

Group type: EXPERIMENTAL
Intervention: tixagevimab/cilgavimab (300 mg)
Number of subjects: 229
Study: 39448991

Group type: EXPERIMENTAL
Intervention: Polyethylene fiber reinforced bulk fill resin composite restorations
Number of subjects: 240

Group type: COMPARATOR
Intervention: Bulk fill resin composite restorations
Number of subjects: 240
Study: 39448999

Group type: EXPERIMENTAL
Intervention: Six-monthly PrEP dispensing with interim HIV self-testing (HIVST)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard-of-care three-monthly PrEP dispensing with clinic-based HIV testing
Number of subjects: 55
Study: 39449056

Group type: EXPERIMENTAL
Intervention: Functional exercise program (45-minute sessions, twice per week for 14 weeks)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Functional exercise program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Stretching exercise group (flexibility exercises, same duration and frequency)
Number of subjects: 82
Study: 39449089

Group type: EXPERIMENTAL
Intervention: After-school program voucher only
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Summer day camp voucher only
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: After-school and summer day camp vouchers
Number of subjects: 480

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 480
Study: 39449120

Group type: EXPERIMENTAL
Intervention: 2021 CKD-EPI equation
Number of subjects: 15773

Group type: COMPARATOR
Intervention: 2009 CKD-EPI equation
Number of subjects: 15773
Study: 39449387

Group type: EXPERIMENTAL
Intervention: Knowledge of Female Body Scale-KFB
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Brief Health Literacy Screening Tool-BRIEF
Number of subjects: 301
Study: 39449962

Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program (TWP) - 12-week exercise intervention with individualized and group behavior change support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program (TWP) - 12-week exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program (TWP)
Number of subjects: 0
Study: 39449979

Group type: EXPERIMENTAL
Intervention: Leighton-Rex scale
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CC-CLEAR scale
Number of subjects: 24
Study: 39450267

Group type: EXPERIMENTAL
Intervention: Alternate-day modified fasting (ADMF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous low-calorie diet (LCD)
Number of subjects: 20
Study: 39450294

Group type: EXPERIMENTAL
Intervention: CT-derived fractional flow reserve (CT-FFR)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Automated module for CT-FFR evaluations
Number of subjects: 108
Study: 39450437

Group type: EXPERIMENTAL
Intervention: 2-year multidomain lifestyle intervention including dietary advice, exercise, cognitive training, and vascular risk management
Number of subjects: 568

Group type: COMPARATOR
Intervention: Regular health advice control group
Number of subjects: 568
Study: 39450683

Group type: EXPERIMENTAL
Intervention: Stapokibart 300 mg every 2 weeks
Number of subjects: 476

Group type: COMPARATOR
Intervention: Switching from placebo to stapokibart 300 mg every 2 weeks
Number of subjects: 476
Study: 39450717

Group type: EXPERIMENTAL
Intervention: OCT analysis
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Stent underexpansion
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 1-year incidence of target vessel failure
Number of subjects: 297
Study: 39450752

Group type: EXPERIMENTAL
Intervention: Microvascular inflammation without evidence of an antibody-mediated response
Number of subjects: 6798

Group type: EXPERIMENTAL
Intervention: Antibody-mediated rejection
Number of subjects: 6798

Group type: EXPERIMENTAL
Intervention: Probable antibody-mediated rejection
Number of subjects: 6798

Group type: EXPERIMENTAL
Intervention: Newly recognized microvascular inflammation phenotypes
Number of subjects: 6798
Study: 39450762

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Number of subjects: 30
Study: 39450759

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 39450934

Group type: EXPERIMENTAL
Intervention: Music therapy (6 weekly individual sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Social attention control (6 weekly sessions)
Number of subjects: 92
Study: 39451095

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 599
Study: 39451783

Group type: EXPERIMENTAL
Intervention: Prostate Cancer Patient Empowerment Program (PC-PEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39452487

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 158
Study: 39452792

Group type: EXPERIMENTAL
Intervention: Telenursing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39452892

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39452894

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39452950

Group type: EXPERIMENTAL
Intervention: D-RVd followed by D-R maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: RVd followed by R maintenance
Number of subjects: 0
Study: 39453348

Group type: EXPERIMENTAL
Intervention: Patient education about the operative process and pain management
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no patient education)
Number of subjects: 52
Study: 39453356

Group type: EXPERIMENTAL
Intervention: Survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39453357

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39453394

Group type: EXPERIMENTAL
Intervention: Cervex-Brush
Number of subjects: 160

Group type: COMPARATOR
Intervention: Orcellex
Number of subjects: 160
Study: 39453395

Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Radical hysterectomy
Number of subjects: 800
Study: 39453400

Group type: EXPERIMENTAL
Intervention: PLLA-SCA (8 mL of sterile water + 1 mL of 2% lidocaine)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: PLLA-SCA
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 67
Study: 39453454

Group type: EXPERIMENTAL
Intervention: Mesh technique
Number of subjects: 239

Group type: COMPARATOR
Intervention: RTL technique
Number of subjects: 239
Study: 39453550

Group type: EXPERIMENTAL
Intervention: glo HTPs (Standard Mode)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: glo HTPs (Boost Mode)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual Brand (UB) cigarettes
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 75
Study: 39453705

Group type: EXPERIMENTAL
Intervention: PSP Wellbeing Course (Internet-delivered cognitive behavioral therapy)
Number of subjects: 41
Study: 39453735

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study: 39453738

Group type: EXPERIMENTAL
Intervention: IV ferric derisomaltose (FDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39453772

Group type: EXPERIMENTAL
Intervention: Iptacopan (200 mg) twice daily for 24 months
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 39453837

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 6609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609
Study: 39453840

Group type: COMPARATOR
Intervention: Interpectoral-pectoserratus block (single block)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Interpectoral-pectoserratus combined with deep parasternal intercostal block (combined block)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combined block
Number of subjects: 116

Group type: COMPARATOR
Intervention: Single block and combined block
Number of subjects: 116
Study: 39453950

Group type: EXPERIMENTAL
Intervention: Childhood Early Oral Aging Syndrome (CEOAS) index for the primary dentition
Number of subjects: 0
Study: 39454044

Group type: EXPERIMENTAL
Intervention: Comparison micro-interventions (days 4-5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Support micro-interventions (days 6-7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall micro-intervention approach
Number of subjects: 30
Study: 39454050

Group type: EXPERIMENTAL
Intervention: Kidney action team recommendations through electronic health record
Number of subjects: 4003

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4003
Study: 39454076

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 39454079

Group type: EXPERIMENTAL
Intervention: Lower perceived social support (PSS)
Number of subjects: 178
Study: 39454196

Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow (PEF) feedback
Number of subjects: 354

Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 354
Study: 39454227

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg once daily
Number of subjects: 16